In a prospective cohort study, information on clinical parameters, tests and molecular markers is often collected. Such information is useful to predict patient prognosis and to select patients for targeted therapy. We propose a new graphical approach, the positive predictive value (PPV) curve, to quantify the predictive accuracy of prognostic markers measured on a continuous scale with censored failure time outcome.
INTRODUCTION
A common research question in modern medicine is: can putative markers predict future progression of disease? We consider a marker to be any measurement with the potential to signal onset or progression of disease. In disease screening and prognosis, markers that predict future onset or progression of disease are sought. In epidemiology, identified risk factors for many diseases are routinely used in public health practice to classify subjects in regards to risk of future disease events. In these settings predictive markers can be used to stratify patients according to future risk of a (bad) outcome. This leads to more refined treatment or monitoring strategies. Before adopting a marker in practice, however, (i) its predictive accuracy must be quantified, and (ii) it must be compared with other potential markers, including existing prognostic systems, so that the best marker is selected for public health practice.
There are two main approaches to describing the accuracy of a dichotomous marker, Y , where the binary outcome is D (e.g., diseased D = 1 versus not diseased D = 0). The retrospective measures are the true and false positive fractions (TPF, FPF), also known as sensitivity and 1-specificity. These are often of interest in early phases of biomarker studies, since they quantify the extent to which the marker reflects the true outcome and can be calculated directly from case-control studies.
However, positive and negative predictive values (PPV, NPV), the prospective measures, are of more interest to the end users of the test, the clinician and the patient, since they quantify the subject's risk of the outcome, D, given the test result Y .
Calculation of the PPV and NPV is typically performed with a cohort study.
The PPV and NPV are defined for dichotomous tests. No standard definition exists when biomarker Y is continuous. We propose to follow the approach of Moskowitz and Pepe (2004b) , who defined for 0 ≤ v ≤ 1 PPV(v) = P {D = 1|F (y) ≥ v} and NPV(v) = P {D = 0|F (y) < v}, where F is the cumulative distribution function of Y . They plot PPV(v) versus v, where subjects with marker values at or above the vth population percentile are considered as test positive (i.e., F (y) ≥ v), and those below are regarded as negative. Note that NPV(v) is a function of v, PPV(v) and the prevalence ρ, i.e., NPV(v) = 1 − {ρ − PPV(v)(1 − v)}v −1 .
The receiver operating characteristic (ROC) curve is a plot of TPF(c) = P (Y ≥ c|D = 1) versus FPF(c) = P (Y ≥ c|D = 0) for c ∈ (−∞, ∞), generalizing the notion of (TPF,FPF) to continuous data by thresholding the marker. The PPV curve is a natural analogue of the ROC curve for generalizing the notion of predictive value to continuous markers. Importantly, using v as the X-axis rather than the raw marker value provides a common scale for different markers that may be incomparable with respect to their raw values. Moreover, since v is the proportion of the population testing negative with the marker, it makes sense to compare the PPVs of markers when they are rescaled to have equal vs. This highlights the need to consider both the positivity probability, 1 − v, and the associated PPV(v) when evaluating a marker.
We generalize the definition of the PPV curve to outcome variables that are event times. Specifically, for an event time T , we define for a marker Y measured at baseline
A number of approaches to summarizing the predictive accuracy of a continuous marker or covariate are available (Begg et al., 2000) . Perhaps the most commonly used approach in practice is to simply report the hazard ratio estimated from a Cox regression analysis. This, however, ignores absolute risks and the distribution of subjects across risk levels, fundamental aspects of the predictive value of a marker. Other popular approaches include an R 2 summary as the proportion of variation explained by covariates (Schemper and Henderson, 2000) and the Brier score, a measure of residual variation (Graf et al., 1999) . However, these measures may lack clinical relevance.
The notion of explained variation or degree of separation cannot be translated into a clinically meaningful quantity that is easily understood by clinicians and patients.
Furthermore, these measures do not easily facilitate formal comparisons between two markers, and they do not distinguish between different types of errors.
We propose a new way of quantifying the predictive accuracy of prognostic markers measured on continuous scale. In contrast to other suggested measures of predictive accuracy for survival data, we seek a measure that is simple and meaningful for clinical practice, amenable to the comparison of multiple markers, and flexible in its assumptions about the underlying model and censoring mechanism.
ESTIMATION
We consider a prospective study where each subject denoted by the subscript i has a marker Y i measured at the baseline. We let F (y) = P (Y ≤ y) denote the cumulative distribution function and f (y) the corresponding density function. Also let T i be the time to failure for subject i. We assume that T i may be censored at time C i , and we only observe X i = min(T i , C i ) and an associated censoring indicator ∆ i where
In addition, we assume independent censoring such that C i is conditionally independent of the event time T i given marker Y i . Although valid estimation of the PPV curve does not depend on the requirement that risk P (T |Y = y) be a monotonic function of Y , the assumption is desirable in a setting where a biomarker threshold value is used for clinical decision making. For example, rising prostate specific antigen (PSA) may predict poor disease-free survival in patients with prostate cancer. By convention we assume that larger values of Y are associated with higher risks of failure.
2·1 The PPV Curve
We define the PPV curve as a plot of PPV(t, v) = P {T < t|F (y) ≥ v} versus v, for v in an open interval of (0, 1). On the x-axis it shows the proportion of subjects testing positive when a positive biomarker test is defined as exceeding the threshold corresponding to the vth percentile of Y in the population:
On the y-axis it shows the risk of an event by time t for subjects who satisfy that positivity criterion. A horizontal line corresponding to the marginal event time probability P (T < t) serves as a benchmark PPV curve for completely uninformative markers. More informative markers have PPV curves that rise more steeply and reach higher levels.
Some appealing attributes of the PPV curve for practical use include its ease in interpretation and visualization of useful quantities. For example, if only subjects in the top 10 th percentile of risk are eligible for an intervention study, one can observe the expected proportion of such subjects with an event by time t, PPV(t, 0.90).
Conversely if a fraction p to have an event by time t is desired, one can observe the corresponding fraction 1 − v of the population that will be required to test positive with the marker, PPV −1 (t; p) = v, from a monotonic PPV curve. The PPV curve also provides a common meaningful scale for comparing multiple markers. Lastly, the PPV curve can be used to suggest thresholds that are optimal for defining biomarker positivity. Although PPV curves have been used in the applied literature (e.g. Blanks et al., 2001 ) they have only recently been formally considered in the statistical literature (Moskowitz and Pepe, 2004b) . We extend the idea from the application to binary outcomes considered by Moskowitz and Pepe (2004b) to event time outcomes.
2·2 Estimation: Non-parametric Approaches
We first describe a class of nonparametric approaches. Such methods do not impose modeling assumptions on the relationship between the marker and survival and therefore will be broadly applicable to many practical settings.
Under independent censoring: We first consider the case where the censoring process C does not depend on Y . A natural estimator for PPV(t, v) can be obtained by estimating the survival distribution based on the subset of subjects with
is the empirical distribution function of Y . The survival probability function can be estimated nonparametrically using either the Aalen-Nelson or Kaplan-Meier estimator. Since these two estimators are asymptotically equivalent, we only consider the Aalen-Nelson estimator. Specifically, let Λ v (t) be the cumulative hazard function of T among subjects with
where
Under marker dependent censoring: Here, we allow C to depend on Y , but assume that T remains independent of C conditional on Y . In the presence of such dependence, PPV(t, v) is subject to bias. For example if individuals with lower marker values tend to be censored earlier then we may expect PPV(t, v) to be biased downward. This problem often arises in situations where a prognostic biomarker is available and the frequency of follow-up efforts is influenced by the marker value measured at baseline. For example, in many AIDS studies individual's censoring status may be related to CD4 counts, a well-accepted marker for survival. To account for marker dependent censoring, we note that
thus S y (t) can be estimated non-parametrically. In particular we consider the kernel estimator for S y (t) (Beran, 1981; Dabrowska, 1989; Akritas, 1994) :
Here K is a given symmetric smooth kernel density function, and h is the bandwidth such that nh 2 → ∞ and nh 4 → 0 as n → ∞. A plug-in estimator for PPV(t, v) based on the bivariate distribution function is
2·3 Estimation: A Semi-parametric Approach
The proposed PPV curve can also be estimated using a regression model approach. Compared with a nonparametric estimator, parametric methods are usually more efficient when the underlying assumptions hold. In addition, marker-dependent censoring is easily accommodated. As an illustration, we assume a proportional hazards model for survival time of the form λ(t|Y
the cumulative baseline hazard function. A plug-in estimator for PPV(t, v) based on the conditional survival probability is
where β is the maximum partial likelihood estimator of β 0 and Λ 0 (t) is the Breslow estimator of Λ 0 (t).
To construct a PPV curve, one can select a grid of points v ∈ (0, 1), and estimate the corresponding values of PPV{t, F −1 (v)}. For example, the key quantity
can be calculated by first estimating the weighted Aalen-Nelson estimator at each y, and then integrating over the range of y with
2·4 Evaluating and Comparing Predictive Values of Markers
A few summaries based on the PPV curve are of interest. For example, we may wish to make inference about risk of t-year mortality for these 100(1−v)% individuals testing positive, i.e., PPV(t, v) at specified values for v and t; or the fraction of the population testing positive that corresponds to a PPV value of p by year t, i.e., the inverse PPV −1 (t; p) at specified values for p and t if the curve is monotonic.
A fundamental attraction of the PPV curve is that it provides a common meaningful scale for comparing markers. We will first consider comparing the PPV(t, v) of two markers, Y 1 and Y 2 , at any given (t, v) or jointly over a set of points {(t k , v k ), k = 1, ..., K}. Typically marker data arise from study designs where both markers are measured on each individual. Based on such paired data, one may estimate the
using the aforementioned PPV estimators.
INFERENCE IN LARGE SAMPLES
We show in Appendix A that PPV(t, v) is uniformly consistent for PPV(t, v). Furthermore, the process
and converges weakly to a zero mean Gaussian process, where
To obtain a pointwise confidence interval and a simultaneous confidence band for PPV(t, v), we will use the resampling method (Parzen et al., 1994) which has been successfully extended to approximate the distribution of a process (see Park and Wei (2003) for details). Specifically, we first generate J independent samples of standard normal random variables, {N (j)
with η i (t, v) obtained by replacing all theoretical quantities in η i (t, v) by their empirical counterparts. The function ∂Λ(t, c)/∂c in η i (t, v) can be estimated with the finite difference estimator. Conditional on the data, the process W v (t) has the same limiting covariance function as that of W v (t)}. Now, based on a functional delta method, we construct 100(1 − α)% confidence intervals for PPV(t, v) as
α is the 100(1 − α/2)th percentile of the standard normal for point-wise confidence intervals, and d α is obtained as the 100(1 − α)th
The uniform consistency of PPV(t, v) follows directly from the uniform consistency of Λ y (t) and F (y). To obtain interval estimates of PPV(t, v), we show in v) , and converges weakly to a zero-mean Gaussian process, where
The distribution of W v (t) can be approximated via the resampling methods by estimating all the unknown quantities in ξ i (t, v) empirically. Note that the density function f (·) in ξ i (t, v) can be estimated using a kernel estimator. Confidence intervals for PPV(t, v) can be constructed accordingly.
In Appendix C, we show that W * v) , and converges weakly to a zero-mean Gaussian process, where ζ i (t, v) is defined in (C·1). Subsequent inference procedures follow that of PPV(t, v). To make inference about PPV −1 (t; p), we note that by the stochastic
. Thus the distribution of PPV −1 (t; p) can also be derived similarly based on that of W v (t).
To test whether two markers measured simultaneously on the same subject have significantly different predictive values, we test the hypothesis
To obtain a confidence interval for rPPV(t, v), we consider its log-transformation and note that by a continuous mapping theorem, n 1 2 {log{r PPV(t, v)}−log{rPPV(t, v)} is asymptotically equivalent to n
whose distribution can be approximated using the resampling method as well.
Simulation studies were performed to examine the finite sample properties of the proposed procedures and to investigate the impact of model assumptions on the two classes of estimators. The results suggest that our methods provide reasonably unbiased estimates and our nonparametric estimators are quite robust. See JASA supplemental web site for details on simulation results.
EXAMPLE: THE SEATTLE HEART FAILURE MODEL FOR PRE-DICTION OF SURVIVAL IN HEART FAILURE
We illustrate our methods with an example in the context of predicting survival among patients with heart failure. Heart failure is a serious condition with highly variable outcome. Often clinicians need to counsel patients about prognosis and to make decisions about medications, transplantation and end of life care. The Seattle Heart Failure Model (SHFM), a multivariate Cox model, was derived in a cohort of heart failure patients and prospectively validated in 5 additional cohorts with nearly 10,000 heart failure patients. The model incorporates 13 variables relating to clinical status and laboratory parameters with higher values of the SHFM score being more indicative of worse prognosis. Levy et al. (2006) have provided a complete description.
First we wish to quantify the accuracy of the SHFM score for predicting t-year survival. We consider data from the Val-HeFT study, a cohort independent of the original derivation trial. Val-HeFT is a randomized trial in 5,010 patients in 16 countries.
The median follow-up was 2 years, with 976 death observed over the course of the study. Since there was no prespecified cutoff value for defining a positive result, timedependent PPV curves provide graphical displays that characterize the risk of death by t year among the (1 − v)*100% of the population with a positive test, across a full spectum of v ∈ (0, 1). We considered P P V curves based on the three proposed estimators. A proportional hazards model of the form λ(t|Y ) = λ 0 (t)exp(β SHFM score) was used for PPV * (t, v). For illustration we randomly selected 1000 patients from this study. For PPV(t, v), let c denote the standard deviation of SHFM scores, the bandwidth h was chosen to be c/n 1/3 ≈ 0.07. The estimates are presented in Table   1 . If a PPV value p at t is considered for clinical decision making, what percentage of the population will be selected based on the SHFM score? We address this question by studying PPV −1 (t = 1; p). For this study, if the goal is to achieve a PPV value of 0.25 by year one, then it requires that approximately 15% (95%CI: (0.06, 0.24))(i.e., 1-PPV −1 (t = 1; p = 0.25)) of the population test positive, i.e., we choose the 85th percentile of the marker (score) as the threshold for defining positivity.
One imminent question here is whether the SHFM provides improved prognostic potential over existing heart failure models. The Toronto heart failure model (THFM) was derived in hospitalized patients using information identified shortly after hospital presentation (Lee et al., 2003) . It is of interest to compare the capacities of the two models for predicting 1-, 2-and 3-year mortality risk in populations that reflect broad range of systolic heart failure. Both prognostic scores appear to be signifi- We compare the predictive accuracies of the SHFM score and THFM score using data from the entire cohort of 5010 patients. In Table 2 , we list for selected v and for t = 1, 2, and 3 year the estimated rPPV and their 95% pointwise confidence intervals and simultaneous confidence band calculated over the region v = [0.05, 0.95]. All rPPV(t, v)s with v ≥ 0.90 are significantly higher than 1, however only those for t = 2 remain significant if the 95% confidence bands are considered. We conclude here that the SHFM is more predictive of 1-, 2-, and 3-year mortality risks than THFM when a small fraction of the population is selected for further treatment.
DISCUSSION
In this paper we have introduced a graphical approach for quantifying and comparing the prognostic accuracies of continuous markers with censored failure time outcome.
Observe that a marker may be useful for prediction but perform poorly for classification. Gail and Pfeiffer (2005) noted that performance criteria of markers for selecting patients for cancer prevention interventions are not the same as those required of markers for cancer screening. Our motivating applications are concerned with predic-tion and risk stratification. Therefore it is appropriate to evaluate them in terms of their prospective accuracy parameters, PPV and NPV. Much work in the literature has focused on evaluating the performance of a marker as a classifier, i.e., with respect to its retrospective accuracy; however clinically meaningful methods for quantifying the prospective prognostic accuracy have not been well developed (Moskowitz and Pepe, 2004a) . The work presented here offers such a method.
Several approaches for estimating the PPV and NPV curves are studied. The semiparametric approach is more efficient than the nonparametric procedures, but can be sensitive to modeling assumptions about how the marker is related to survival. The two nonparametric approaches are more flexible, and the kernel smoothing estimator we considered also takes into account marker dependent censoring. These methods will be broadly applicable to many practical settings.
There are two considerations one must take into account when adopting the PPV curve in practice. First, PPVs and NPVs depend on prevalence of the outcome; consequently they reflect characteristics of the cohort that gave rise to the curves. It is therefore important to assure that the research cohort indeed constitutes a random sample of the general population of interest where the clinical decision rules will be applied (see Pepe et al. (2007) for a discussion of this issue). The Val-HeFT study consists of participants from 16 countries. It is conceivable that prospective accuracy might be different when applied to an individual country and it should be further evaluated in subcohorts with different heart failure rates. Second, in this paper we considered only the predictive performance of a baseline marker. Frequently in practice repeated measurements are collected for monitoring disease progression, and the 'updated' prediction of risk as a function of current and past marker information is of interest. Estimating such a quantity requires more deliberation. Further investigation on adopting the notion of PPV curve for longitudinal markers is warranted.
APPENDIX
Throughout we assume that the joint density of T , C and Y is continuously differentiable and the marker Y is bounded. We consider v ∈ [p l , p u ] ⊂ (0, 1) and
where τ 1 and τ 2 are given constants such that P (X < τ 1 ) > 0 and P (X > τ 2 ) > 0. In addition, we assume that the first and second order derivatives of F (y) are bounded away from 0 for y ∈ (−∞, ∞). Λ(t, c) is continuously differentiable with sup s,c {Λ(t, c) +Λ(s, c)} < ∞, whereΛ(s, c) = ∂Λ(s, c)/∂c.
A. Asymptotic Properties of PPV(t, v)
Since PPV(t, v) = 1 − exp{ Λ v (t)} is a smooth monotonic transformation of Λ v (t), we first derive the asymptotic properties for Λ v (t). To this end, we definē 
It follows from standard empirical processes theory (Pollard, 1990) 
i η i1 (t, c) and converges weakly to a zero mean Gaussian process in (t, c), where
∂Λ(s, c)/∂c. Here and throughout, the o p (1) is uniform in t and v. This, together with the weak convergence of the quantile process n
is asymptotically equivalent to n
, where
and f (y) = dF (y)/dy. It then follows from a functional central limit theorem (Pollard, 1990 ) that W v (t) converges weakly to a zero-mean Gaussian process.
B. Asymptotic Properties of PPV(t, v)
We require the same conditions as specified in Du and Akritas (2002) . Briefly, K(·)
is a twice continuously differentiable symmetric probability density function with bounded second derivative. To derive the large sample distribution for PPV(t, v), we
To approximate the distribution of W 1v (t), we note that
This, together with a Taylor series expansion and Lemma A.3 of Bilias et al. (1997) ,
the asymptotic expansions for Λ y (t) in Du and Ariktas (2002) , we have
This, together with a functional central limit theorem, implies that W v (t) converges weakly to a zero-mean Gaussian process.
C. Asymptotic Properties of PPV * (t, v)
We assume the same regularity conditions as in Andersen and Gill (1982) , who showed that n 1 2 ( β − β 0 ) is asymptotically normal and n 1 2 ( Λ 0 (t) − Λ 0 (t)) converges weakly to a Gaussian process. Similar to the derivation for PPV(t, v), following standard empirical processes theory (Pollard, 1990) , we can show that the process W * v (t) = n 1/2 { PPV * (v, t) − PPV(v, t)} = n Horizontal lines are for P (T < 1 year) in the PPV plot and P (T ≥ 1 year) in the NPV plot.
